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Abstract
Background: It has been reported for over the past decade that the use of selective serotonin
reuptake inhibitors (SSRI's) may associate with the emergence of apathy. The authors hypothesized
that depressed patients treated with SSRI's would show more signs of apathy than patients treated
with non-SSRI antidepressants. This case control study was conducted to investigate the possibility
of the association between SSRI use and the occurrence of apathy.
Methods: Baycrest Centre for Geriatric Care's Day Hospital Database of elderly depressed
patients who received antidepressants was divided into 2 groups depending on antidepressant use
at discharge: SSRI user group-SUG, and non-SSRI user group-NSUG. Apathy scales developed by
the authors were selected from the Geriatric depression Scale (GDS) and the Hamilton Rating
Scale for Depression (HAMD), and were titled as GDS-apathy subscale (GAS) and HAMD-apathy
subscale (HAS). Demographic data, baseline apathy, underlying medical conditions and medication
use were studied. Proportion, analysis of variances, Chi-square test, odds ratio with 95%
confidence interval were reported.
Results: Among 384 patients (160 SUG and 224 NSUG), mean GDS and HAM-D at discharge
were 12.46 and 10.61 in SUG, and were 11.37 and 9.30 in NSUG, respectively. Using GAS for
apathy assessment, 83.7% of patients in SUG and 73.4% in NSUG stayed apathetic at discharge. As
evaluated by HAS, 44.2% of patients in SUG and 36.5% in NSUG stayed apathetic. SSRI use was not
a predictor of apathy at admission, while it was at discharge, p = 0.029. The SUG showed more
patients with apathy than that found in NSUG (adjusted OR = 1.90 (1.14–3.17). Age 70–75 years
tended to be a predictor for the apathy (p = 0.058). Using HAS, age 70–75 years and living situation
were associated with apathy at discharge, p = 0.032 and 0.038 respectively.
Conclusion: Even though depression was improved in elderly patients receiving antidepressants,
apathy appeared to be greater in patients who were treated with SSRI than that found in patients
who were not. Frontal lobe dysfunction due to alteration of serotonin is considered to be one of
the possibilities.
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Background
Apathy is a common behavioral syndrome characterized
as a decrease in (or lack of) interest, motivation, or initia-
tion of action [1,2]. Apathy can be found among patients
with depression, psychosis, dementia, traumatic brain
injuries, etc [1]. The syndrome is associated with poor
functioning, poor illness outcome, and a negative impact
on caregivers. Although apathy and depression are
related, the two syndromes are distinct from each other
[1,3,4].
Selective serotonin reuptake inhibitors (SSRI's) are widely
used in treating depressive and anxiety disorders in elderly
persons. Over the past decade, four case reports revealed
12 cases, receiving various SSRI's, who developed apathy,
amotivation or a frontal lobe syndrome [5-8]. However,
all of these cases were adults or adolescents.
Frontal-subcortical dysfunction is proposed as a cause of
apathy and depression [1,2,9]. In frontal areas, there is a
counterbalance between serotonergic and adrenergic
function. Two randomized controlled trials, comparing
SSRI's and selective noradrenaline reuptake inhibitor
(NARI) in depression, reported that serotonergic manipu-
lation shows less improvement in motivation, at the
group level of analysis, than do noradrenergic agents,
even though depressive symptoms are improved [10,11].
The effect of SSRI's exposure on the risk for apathy has not
been well studied. We conducted a case control study to
evaluate the risk of apathy among elderly depressed day-
hospitalized patients treated with, or without, SSRI's. The
study utilized an existing database, which has recorded
clinical data, at admission and discharge, from patients
treated in the Day Hospital for Depression at Baycrest.
The authors hypothesized that depressed patients treated
with SSRI's would show more signs of the apathy syn-
drome at discharge from the Day Hospital, than patients
treated with non-SSRI antidepressants. Therefore, the pur-
pose of this study was to investigate the possible associa-
tion between SSRI use and the apathy syndrome in an
elderly depressed group treated in day hospital setting.
Methods
Information related to all depressed elderly given an anti-
depressant in the Day Hospital from April 1986 to January
2005 was identified in the database. Apathetic and non-
apathetic groups were defined on the basis of data
recorded at discharge from day hospital (see below). The
authors also divided the patients into 2 groups depending
on information regarding antidepressant used at dis-
charge: 1) SSRI's user group (SUG) and 2) Non-SSRI's user
group (NSUG).
Data from first admission generally included demo-
graphic and clinical characteristics of the study sample,
and data related to potential confounding variables.
Scales representing apathy were extracted from the pri-
mary scales used for assessing the patients at admission
(to control for baseline apathy) and were compared
between both groups at discharge. These scales utilized
items from the Geriatric Depression Scale (GDS) [12] and
the 21-item Hamilton Rating Scale for Depression
(HAMD-21) [13]. Items selected (see below) were chosen
by consensus of the principal investigator and two local
experts on the Apathy Syndrome (Drs. Tiffany Chow and
Robert van Reekum).
Study population
Study population included individuals aged 55 and older
who had been diagnosed as depressed and who received
any type of antidepressant while in the Day Hospital.
Patients who did not receive pharmacological therapy
were excluded from the study. In order to avoid potential
biases, in the case of multiple admissions, only the data
from the first admission was used.
Scales for apathy
Scales for directly assessing apathy were not included in
the database. Thus, the investigators retrieved some asso-
ciated items from the GDS and the HAMD-21 for apathy
evaluation.
From the GDS, the following items were used: item 2
(Have you dropped many of your activities and inter-
ests?), item 12 (Do you prefer to stay at home, rather than
going out and doing new things?), and item 20 (Is it hard
for you to get started on new projects?). The extracted
scale from the GDS was titled the GDS-apathy subscale
(GAS); scores range from 0 to 3. A score of '0' represented
'non-apathy', and scores from 1–3 were grouped as 'apa-
thy' in this study.
From HAMD-21, item 7 was retrieved. The question is
about 'Work and activities'; score of 0 = No difficulty; 1 =
Incapacity, fatique or weakness related to activites, work
or hobbies; 2 = Loss of interest in activites, hobbies or
work-reported by patient or listlessness, indecision and
vacillation (has to push self); 3 = Decrease in actual time
spent in activities or decrease in productivity; 4 = Patient
engages in no activity or fails to perform unassisted). The
item was titled HAMD-apathy subscale (HAS); scores
range from 0–4. Scores of 0–1 on this item were defined
as 'non-apathy' per se, and scores from 2–4 were grouped
as 'apathy'.
Potential confounders
Age, gender, baseline apathy (per the scale developed by
the authors), primary language used, living situation,Annals of General Psychiatry 2007, 6:7 http://www.annals-general-psychiatry.com/content/6/1/7
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underlying medical conditions, smoking, and marijuana
(or other substance use) might all be possible confound-
ing factors [2,14]. Not only antidepressants are used
amongst patients in Day Hospital, but also other medica-
tions. Thus, information on the use of other drugs that
might induce apathy through their pharmacological
action was also studied. These drugs might include seda-
tive-hypnotic drugs, sedating drugs, anticholinergic drugs,
antiepileptic drugs, antipsychotic drugs, etc.
For all medication use, only the name of the medication
was recorded in the database. Data regarding dosage, date
started and discontinued, etc was not available.
Underlying or co-morbid medical conditions which
might be confounders include: 1) diseases of the central
nervous system such as Alzheimer's disease, cerebrovascu-
lar diseases, Parkinson's disease, etc., 2) endocrine disor-
ders such as hyperthyroidism, hypothyroidism,
panhypopituitarism, and 3) nutritional diseases such as
vitamin deficiency.
Statistical analysis
Demographic data (such as gender, marital status, living
situation, etc.) and diagnoses were reported by propor-
tion. Age and duration of stay were calculated by mean. In
order to compare means of age, gender, length of stay,
education, marital status, living status, primary language
used, total GDS, total HAMD-21, GAS and HAS at both
admission and discharge in SUG and NSUG, an analysis
of variance (ANOVA) was applied. A Chi square test was
calculated for analyzing the differences among comorbid
diseases and medication use between the two groups.
Multivariate logistic regression analyses were conducted
for analyzing the apathy risk, and for assessing the predic-
tive variables. Odds ratio (OR) with 95% confidence
interval was calculated for the apathy syndrome between
SUG and NSUG.
Results
The first admission data from 824 elderly depressed
patients were received from the database. Six hundred
(600) cases received antidepressants. Three hundred and
eighty four cases had complete GDS for both admission
and discharge and were included in this study.
With respect to Axis I diagnosis, 249 patients (64.8%) had
been diagnosed with major depressive disorder, 18.2%
had major depressive disorder and dysthymia (or 'double
depression'), 5.7% had dysthymia, 5.2% were patients
with depressive disorder due to a general medical condi-
tion, 4.7% were bipolar depressed patients, and 1.3% had
adjustment disorder with depressed mood.
Some patients had comorbid psychiatric disorders; 63
cases had anxiety disorders or other neuroses, 29 patients
suffered from substance related disorders, and 12 cases
had psychotic disorders.
The demographic data, scores for depression, selected
apathy scores, co-morbid or underlying axis III diseases
and other medication use during the stay are indicated in
Table 1. Due to missing HAMD, the data related to the
scale were available in 290 patients.
The number of patients on SSRI's was 160, and 224
received non-SSRI antidepressants, i.e. heterocyclic anti-
depressants (HCAs), mono-amine oxidase inhibitors
(MAOIs), serotonin and noradrenaline reuptake inhibitor
(SNRI), noradrenergic and specific serotonergic antide-
pressant (NaSSA), serotonin reuptake and 5HTs inhibitor,
and atypical noradrenaline and dopamine reuptake
inhibitor. The SSRI's including in descending order of fre-
quency of use: sertraline, paroxetine, fluoxetine, citalo-
pram, and fluvoxamine.
ANOVAs revealed no significant differences between SUG
and NSUG with respect to age, gender, length of stay, level
of education, marital status, living status, primary lan-
guage used, mean HAMD-21 at admission, or mean GAS,
GDS, HAS at both admission and discharge (p > 0.05).
Mean HAMD-21 at discharge in SUG was significantly
greater than that in NSUG (p = 0.046).
In SUG, 153 patients were apathetic (by GAS) at admis-
sion, and 128 patients remained apathetic at discharge.
Two hundred and fourteen patients in NSUG were apa-
thetic at admission, and 157 patients remained apathetic
at discharge. From this data, prevalence of apathy at
admission using GAS was 95.6%, while at discharge, it
was 74.2%. As presented in Table 2, only 290 patients had
completed HAS. In terms of apathy at discharge, as
assessed by the HAS, 34 patients (out of 108) in SUG, and
50 patients (out of 182) in NSUG, remained apathetic.
With regard to the evaluation of the association between
apathy using GAS at admission and all possible variables,
the authors found that demographic data, co-morbid Axis
III diseases and medication used, including SSRI's (p =
0.961), were not predictive factors for apathy at admission
(all p > 0.05). The crude OR was 1.02 (0.38–2.74).
Regarding apathy at discharge using GAS, the length of
stay (p = 0.011) was one of the predictor variables for apa-
thy. The number of people with apathy who were admit-
ted for between 3 and 6 months was less than that in the
groups with shorter or longer stay (p at 3, 4, 5 and 6
months were 0.015, 0.002, 0.008 and 0.045 respectively).
Moreover, age group of 70–75 years tended to be a predic-Annals of General Psychiatry 2007, 6:7 http://www.annals-general-psychiatry.com/content/6/1/7
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tor for apathy (p = 0.058). The number of people with
apathy in this age group tended to be less than in other
groups. Apathy was not related to either co-morbid axis III
diseases or to non-antidepressant medication use (all p >
0.05). SSRI use was one of the predictors for apathy (p =
0.029). The SUG showed more patients with apathy than
in NSUG with a crude OR of 1.71 (1.06–2.76 95% CI)
and an adjusted OR of 1.90 (1.14–3.17 95% CI).
In the evaluation of apathy among the 290 patients who
had complete and valid HAMD-21 data, the authors
found no evidence of predictor variables for apathy at
admission. The variables predicting apathy at discharge
were: age group of 70–75 years (p = 0.032) and living sit-
uation (p = 0.038). SSRI use was not a predictor for apathy
at discharge using the HAS (p = 0.045) with a crude OR of
0.82 (0.49–1.39).
Discussion
The authors acknowledge that the study is limited by the
measurement of apathy used, as it was derived from
depression scales, and has not been validated (beyond
content validation from local experts). The study is, of
course, also limited by the data contained in the database
(e.g. dose of medications not available, duration of use
not available, etc). Despite these limitations, important
relationships between apathy and potential contributors
to apathy (e.g. SSRI use) were found.
In both SUG and NSUG, all apathy scores at discharge
were less than at admission. Therefore, both SSRI's and
non-SSRI's appeared to be efficacious in treating the apa-
thy of depression. Even though there was no difference
between apathy scores as measured by GAS and HAS
between both groups, the difference in the number of
Table 1: Comparison of variables between SUG and NSUG
Variables SUG (n = 160) NSUG (n = 224) Remarks
Demographic data
Mean age (years) 74.6 ± 6.9 75.7 ± 6.9
%Female 72.5 72.3
%Marital status (non-married) 64.4 57.1
%Primary language use (non-
English)
56.3 44.2
%Living status (alone) 45.6 48.2
%Education (< high school) 51.9 49.1
Average length of stay (days) 136.7 ± 36.0 137.3 ± 38.1
Scales
Mean HAS at admission 1.98 ± 0.98 2.08 ± 0.98 a
Mean HAS at discharge 1.13 ± 0.89 0.99 ± 0.89 a
Mean total HAM-D 21 at 
admission
18.57 ± 6.33 18.67 ± 6.27 a
Mean total HAM-D 21 at discharge 10.61 ± 6.48 9.30 ± 6.15 a, p = 0.046
Mean GAS at admission 2.18 ± 0.88 2.13 ± 0.83
Mean GAS at discharge 1.43 ± 1.01 1.31 ± 1.05
Mean total GDS at admission 19.34 ± 6.23 18.75 ± 6.11
Mean total GDS at discharge 12.46 ± 7.45 11.37 ± 6.79
Co-morbid axis III illness
Dementia 5 12
Parkinson's disease 3 8
Stroke 21 29
Head injury 6 5
Hypertension 60 87
DM 27 28
Hyperthyroidism 1 3
Hypothyroidism 26 29
Medication use
Benzodiazepines 89 128
Hypnotics 144 207
Antipsychotics 18 26
a; n = 290, nSUG = 108, nNSUG = 182Annals of General Psychiatry 2007, 6:7 http://www.annals-general-psychiatry.com/content/6/1/7
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cases who remained apathetic at discharge between
groups was different.
Apathy at admission, using both selected scales, did not
have strong relationships with any of the possible predic-
tor variables.
Apathy at discharge was predicted by SSRI use, as indi-
cated by the OR of 1.91 in the SUG (as assessed by the
GAS). To discuss the hypothesis that apathy syndrome is
caused by SSRI use, the criteria of Sir Bradford Hill [15]
will be briefly considered. The 9 criteria are 1) the strength
of the association, 2) the consistency of the association, 3) bio-
logic plausibility, 4) the temporal relationship, 5) the biologic
gradient, 6) its specificity, 7) coherence, 8) experimental evi-
dence, and 9) analogy. However, van Reekum et al. [16]
have proposed that for assessing causation in neuropsy-
chiatry, criteria 1 to 4 are the most relevant.
SSRI use was shown, in this study, to be associated with
apathy. This is consistent with the previous reports [3,5-
8,10,11], in spite of the different settings and age group of
the participants. It is biologically possible that frontal
lobe dysfunction, induced by SSRI's, may be responsible
for the apathy seen in the SUG in this study. There are sev-
eral counterbalances of neurotransmitters in the brain.
With respect to a counterbalance of serotonin and
dopamine, Kapur et al. [17] proposed that prolonged and
excessive serotonin in the synapse may lead to a decrease
in transmission of dopamine in the frontal lobe. A
decrease of dopamine is one of the potential causes of the
apathy syndrome as with the apathy seen in people with
Parkinsonism. Additionally, Golomb et al. [18] stated that
depression is associated with both low serotonin and high
acetylcholine function. High serotonin may cause a
decrease in acetylcholine, and vice versa, which can cause
an increase in dopamine function thereafter. The relation-
ship between serotonin and noradrenaline is another pos-
sible mechanism [10,11]. Desensitization of postsynaptic
5-hydroxytryptamine (5-HT) receptors is a recent finding
resulting in rebound symptoms in prolonged use of par-
oxetine [19]. At present, we do not yet have enough data
to know how altering serotonergic functioning might
cause apathy.
In terms of the temporal relationship between SSRI use
and apathy, this study is limited, as the database lacked
information on start date, and duration of the use of med-
ication.
Length of stay seemed to have a relationship with apathy.
The direction of causation is unclear; prolonged day hos-
pital stay might have caused apathy, or, perhaps more
likely, apathy caused patients, families, and the day hospi-
tal team to consider longer day hospital stays.
Further research, using prospective data (e.g. medication
use), and better validated apathy scales, in large sample
sizes (such as population-based or national surveys) is
supported by the results of this study. The investigation of
the effect on apathy of SSRI users in all age groups will
also be required. Patient education, related to the poten-
tial for SSRI's to cause apathy, should be considered.
Conclusion
Apathy at discharge appeared to be greater in elderly
depressed patients who were treated with SSRI's than that
found in patients were not. Further studies with prospec-
tive design are required. Patients and caregivers should be
informed to be more aware of this potential adverse effect
when using SSRI's. Careful monitoring for apathy, and
consideration of switching antidepressant class in patients
presenting with apathy, should be undertaken in all
patients receiving an SSRI.
Table 2: Number of patients with apathy upon antidepressant use
Antidepressants Apathy using GAS (n = 384) Apathy using HAS (n = 290)
At admission OR At admission OR
Yes No (95% CI) Yes No (95% CI)
SUG 153 7 1.02 b
(0.38–2.74)
77 31 0.82
(0.48–1.39)
NSUG 214 10 137 45
At discharge At discharge
Yes No Yes No
SUG 128 32 1.71 (*)
(1.06–2.76)
34 74 1.21
(0.72–2.04)
NSUG 157 67 50 132
Odds Ratio are presented as crude ratio.
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